Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
Phase 3
Completed
- Conditions
- Breast Neoplasms
- Registration Number
- NCT00034125
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie LY353381's efficacy in ER-positive metastatic breast cancer?
How does LY353381 compare to tamoxifen in terms of progression-free survival in advanced breast cancer patients?
Which biomarkers correlate with LY353381 response in hormone receptor-positive breast cancer trials?
What are the key adverse events associated with LY353381 versus tamoxifen in phase 3 breast cancer studies?
Are there combination therapies involving LY353381 or similar SERMs that improve outcomes in metastatic breast cancer?